The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Highlights from day 3 – hot debates
In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, highlights some of the discussions held on day three of COMy 2022, which included debates on the use of measurable residual disease (MRD) to guide therapy, and whether autologous stem cell transplantation (autoSCT) should be replaced with immunotherapy. Prof. Mohty also highlights the possibility of combining immunotherapies with autoSCT to improve patient outcomes. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
